SEPOY.net
No Result
View All Result
Friday, July 18, 2025
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
No Result
View All Result
SEPOY.NET
No Result
View All Result
Home Health

NIAID awards more than $12 million for the development of antiviral therapies

Nicholas by Nicholas
November 21, 2022
in Health
0
NIAID awards more than  million for the development of antiviral therapies

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, recently awarded more than $12 million to three institutions for the development of antiviral therapies to treat diseases caused by viruses with pandemic potential. NIAID may award approximately $61.5 million total over five years if all contract options are exercised. The new product development contracts are part of the Antiviral Program for Pandemics (APP), which aims to accelerate the discovery, development and manufacturing of antiviral medicines.

READ ALSO

Acorn-based coffee boosts antioxidants with minimal health risk

PAR1 protein found to boost lung fluid drainage during injury

Antivirals are treatments that fight viral infections by acting directly against the virus. Other types of therapies, not the focus of this program, harness the body’s immune system to fight infection. The new contracts will support the development of promising antiviral candidates from late-stage preclinical studies through investigational new drug application-enabling activities and clinical testing.

Alongside the new product development contracts, NIAID already supports nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern. The AViDD Centers conduct research on the early-stage identification and validation of novel viral targets and identification and early-stage characterization of antiviral drug candidates.

The new product development contracts include:

Optimization of Broad-Spectrum Filovirus Inhibitors that Target Viral Glycoprotein

Principal investigator: Terry Bowlin, Ph.D.

Institute: Microbiotix, Inc., Worcester, Massachusetts

Base funding amount: $2,069,416

NIAID contract: 75N93023C00001

Development of a Novel 2-Pyrimidone (SRI-42718) as a Potent Inhibitor of Chikungunya Virus Infection and Disease

Principal investigator: Daniel Streblow, Ph.D.

Institute: Oregon Health and Science University, Portland

Base funding amount: $4,696,452

NIAID contract: 75N93023C00002

Development of an Orally Available Antiviral Drug for Yellow Fever

Principal investigator: Jinhong Chang, M.D., Ph.D.

Institute: Baruch S. Blumberg Institute, Doylestown, Pennsylvania

Base funding amount: $5,493,876

NIAID contract: 75N93023C00003

For more information about the APP, please visit: https://www.niaid.nih.gov/research/antivirals.

Source:

National Institutes of Health

Tags: AllergyAntiviral DrugElectronInfectious DiseasesManufacturingMedical ResearchMicrographPandemicpHResearchVirus

Related Posts

Acorn-based coffee boosts antioxidants with minimal health risk
Health

Acorn-based coffee boosts antioxidants with minimal health risk

July 18, 2025
PAR1 protein found to boost lung fluid drainage during injury
Health

PAR1 protein found to boost lung fluid drainage during injury

July 18, 2025
From chemistry to life: Building synthetic cells with metabolism
Health

From chemistry to life: Building synthetic cells with metabolism

July 17, 2025
Specially engineered antibody delivers RNA therapy to treatment-resistant tumors
Health

Specially engineered antibody delivers RNA therapy to treatment-resistant tumors

July 17, 2025
How can super-resolution technology help study neurotransmission?
Health

How can super-resolution technology help study neurotransmission?

July 17, 2025
Vaccinated women face fewer cervical cancer risks
Health

Vaccinated women face fewer cervical cancer risks

July 17, 2025
Next Post
Cost-saving Medicare Advantage may be a disadvantage for complex cancer surgery patients

Cost-saving Medicare Advantage may be a disadvantage for complex cancer surgery patients

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

About

Sepoy.net is a perfect place for people who want daily updates on news related to business, technology, entertainment, health, cryptocurrency etc.

Contact: hello@sepoy.net

Major Categories

News

Business

Tech

Economy

 

Recent Posts

  • Best online casinos inside 2025 Top ten real cash gambling enterprise sites to possess huge payouts
  • 300 Protects Slot Game: Free Play Eurogrand video slot Casino slot games from the NextGen On the web
  • Because of the 2020, MGM Huge got approved $4,079,830 in the cash that have been illegal proceeds from nv casino Nix’s unlawful playing providers

Pages

  • About Us
  • Contact Us
  • Disclaimer
  • DMCA
  • Home
  • Privacy Policy

© 2023 Sepoy.net

No Result
View All Result
  • Home
  • Business
  • News
  • Health
  • Tech
  • Science
  • Lifestyle
  • Travel

© 2023 Sepoy.net